In China, treatment with osimertinib rather than placebo appears to be an effective and economically accessible option for patients with stage III EGFR-mutated NSCLC with no disease progression during or after chemoradiotherapy, especially in the eastern and central economic regions of China. This evidence concerns the gene EGFR and non-small cell lung carcinoma.